Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Pharm Bull (Tokyo) ; 48(4): 559-62, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10783079

ABSTRACT

In the process development of lovastatin using Aspergillus terreus DRCC 152 in solid state fermentation, we have isolated a new butyrolactone-IV (3) along with the previously reported butyrolactone-I (1) and butyrolactone-II (2) produced under submerged conditions. The structure of compound 3 has been characterized as 3-hydroxy-5-[2-(1-hydroxy-1-methylethyl)-2(R)-2,3-dihydro-benzo[b]furan- 5 ylmethyl]-4-(4-hydroxyphenyl)-5-methoxycarbonyl-(5R)-2,5-dihydro-2 -furanone on the basis of spectroscopic studies. The absolute stereochemistry has been determined by single crystal X-ray diffraction studies. The cytotoxic and antibacterial activities of these compounds were determined.


Subject(s)
4-Butyrolactone/analogs & derivatives , Anti-Infective Agents/chemical synthesis , Antineoplastic Agents/chemical synthesis , Aspergillus/chemistry , 4-Butyrolactone/pharmacology , Animals , Anti-Bacterial Agents , Anti-Infective Agents/pharmacology , Antineoplastic Agents/pharmacology , Bacillus subtilis/drug effects , Enterococcus faecalis/drug effects , Escherichia coli/drug effects , Fermentation , Microbial Sensitivity Tests , Models, Chemical , Models, Molecular , Pseudomonas aeruginosa/drug effects , Staphylococcus aureus/drug effects , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...